

Gasporox - LTM reacceleration expected in Q1 2025

Redeye provides an update on Gasporox following its Q3 2024 report, which was below expectations but continued net sales growth and positive EBITDA. Redeye revises its estimates and fair value range downward. Redeye expects reacceleration in net sales, which it believes will catalyze the share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Gasporox - LTM reacceleration expected in Q1 2025](#)